Madrigal Pharma (MDGL) Announces Pricing of Upsized $600 Million Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- S&P 500, Nasdaq drop as tech megacap declines outweigh upbeat Micron forecast
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at Evercore ISI, 'well positioned to execute on the launch of Rezdiffra'
March 19, 2024 2:50 PM EDTEvercore ISI analyst Liisa Bayko raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $405.00 (from $325.00) while maintaining a Outperform rating.
The analyst comments "With clean label in hand & an additional $600M in the bank, Madrigal is well positioned to execute on the... More
